<DOC>
	<DOCNO>NCT02956967</DOCNO>
	<brief_summary>Non-interventional , non-comparative , national , multi-site , single-arm prospective observational study investigate home administration Nivestim primary prophylaxis chemotherapy-Induced febrile neutropenia</brief_summary>
	<brief_title>Home Administration NivestimTM Primary Prophylaxis Chemotherapy-Induced Febrile Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
	<criteria>Male female patient ≥ 18 year Declaration inform consent sign patient Patients solid tumour malignant haematological tumour Patients prescribed cytotoxic chemotherapy , irrespective current cycle GCSFnaïve patient patient pretreated GCSF receive GCSF last three month enrolment Patients start primary prophylactic treatment use NivestimTM either shorten duration neutropenia prevent occurrence chemotherapyinduced FN Patients chronic myeloid leukaemia ( CML ) myelodysplastic syndrome ( MDS ) Patients hypersensitive one excipients NivestimTM Patients undergo chemotherapy Patients treat curatively secondary prophylaxis GCSF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-Interventional Study</keyword>
</DOC>